FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 17:57:44 29/05/2024 BST | ||
| 1.99 EUR / 2.16 EUR | -2.58% |
|
| Current month | -5.75% | ||
| 1 month | -10.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 2 | -6.10% |
| 28/05/24 | 2.13 | -19.62% |
| 27/05/24 | 2.65 | +1.15% |
| 24/05/24 | 2.62 | -8.07% |
| 23/05/24 | 2.85 | +6.34% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 04:47 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD4ZQ4 |
| ISIN | DE000SD4ZQ40 |
| Date issued | 26/03/2021 |
| Strike | 7,134 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 11.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 53.1 € |
|---|---|
| Lowest since issue | 0.49 € |
| Spread | 0.16 € |
| Spread % | 7.41% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.2
USD
Spread / Average Target
+10.72%
- Stock Market
- Certificates
- Certificat
